Clinical Research

Finally, A Therapy For Lou Gehrig's Disease?

In humans, no therapy for  amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease,  has ever been discovered that could extend lifespan more than a few additional months. ALS was first identified as a progressive and fatal neurodegenerative dis ...

Article - News Staff - Jun 12 2014 - 2:38pm

Amgen Joins National Cancer Institute, Other Companies On Lung-MAP Project

Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a clinical trial program that will use biomarker-driven research and genomic profiling to match ...

Article - News Staff - Jun 16 2014 - 10:16pm

Enrollment For Phase 2 Trial Of INOpulse Pulmonary Arterial Hypertension Treatment Completed

Bellerophon Therapeutics has completed enrollment of its 80-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the ...

Article - News Staff - Jun 17 2014 - 9:30pm

Amgen Drug Improves Ovarian Cancer Treatment, Lowers Recurrence

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix report  in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong ...

Article - News Staff - Jun 20 2014 - 10:30am

Phase I Clinical Trial To Treat Clostridium Difficile Infection Launches

Each year, roughly 250,000 people in the United States require hospital care for Clostridium difficile (C. difficile) infection and at least 14,000 people die from it, according to the U.S. Centers for Disease Control and Prevention (CDC). As a result, th ...

Article - News Staff - Jul 9 2014 - 12:30pm

Minimally Invasive Heart Stents Are Safer

A study has documented the safety benefits of aortic stent grafts inserted during minimally invasive surgery to repair abdominal aortic aneurysms; weaknesses in the body's largest artery that can rupture, causing potentially lethal internal bleeding. ...

Article - News Staff - Jul 9 2014 - 5:00pm

Hyperphosphatemia: Ferric Citrate Long-term Phase 3 Study Results Published

New York, NY- July 24, 2014-- Keryx Biopharmaceuticals, Inc. has published results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), their investigational oral ferric iron-based phosphate binder for the treatment of ...

Article - News Staff - Jul 27 2014 - 8:07am

Achalasia Esophagus Disease Is Autoimmune

Achalasia is a rare disease, affecting 1 in 100,000 people, characterized by a loss of nerve cells in the esophageal wall and manifested as chest pain during eating, weight loss, and regurgitation of food. When we swallow, a sphincter in the lower esophag ...

Article - News Staff - Jul 29 2014 - 12:01pm

C1 Inhibitor Inhibits Antibody-Mediated Rejection Following Kidney Transplant

Results  presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH ...

Article - News Staff - Aug 3 2014 - 9:46am

Xilonix Phase III European Registration Study For Treatment Of Colorectal Cancer

XBiotech has begun its European Phase III study using its novel cancer drug Xilonix™ for the treatment of colorectal cancer. Xilonix is an antiobody works to block a number of processes that tumors use to grow and spread, such as potentially inhibiting the ...

Article - News Staff - Aug 3 2014 - 11:30am